Clinical trial

BI 836845 in Estrogen Receptor Positive Metastatic Breast Cancer

NCT02123823

Drugs and interventions used in this trial

3 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

DRUG · Mapped RxNorm record Everolimus Normalized identity: everolimusView linked drug · Find medicine records · Find other trials using this name

DRUG · Mapped RxNorm record Exemestane Normalized identity: exemestaneView linked drug · Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention BI 836845 Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

BI 836845 in Estrogen Receptor Positive Metastatic Breast Cancer

Design: INTERVENTIONAL · Status: COMPLETED · Phase: PHASE1

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2014-05-15

PhasePHASE1

Conditions

Neoplasmsunresolved

Interventions

EverolimusDRUG · verified · RxNorm: everolimus

ExemestaneDRUG · verified · RxNorm: exemestane

BI 836845DRUG

Sponsors & collaborators

Boehringer Ingelheimlead sponsor

Mapped research locations

MadridSpain4 SeoulSouth Korea2 BarcelonaSpain2 ParisFrance2 TaipeiTaiwan2 BrusselsBelgium2 LiègeBelgium2 LondonUnited Kingdom1 ValenciaSpain1 SevilleSpain1 MarseilleFrance1 ViennaAustria1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT02123823 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.